The regulatory landscape governing cannabis and cannabinoids is changing rapidly, both at the federal and state level. From the de-scheduling of hemp, to FDA’s reconsideration of its policies regarding cannabidiol (CBD) in food and dietary supplements, to the legalization of recreational marijuana in many states, the old regulatory framework is giving way to a new reality.  This presents exciting new opportunities for companies seeking to develop products in this space – but also significant risks.

Scott Lassman has experience working with companies seeking to develop drugs, dietary supplements, food and cosmetics containing ingredients derived from cannabis.

You are invited to contact Lassman Law+Policy for more information on the firm's counsel and advocacy in this rapidly developing area.